| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7503785 | Drug and Alcohol Dependence | 2016 | 38 Pages |
Abstract
CB1 receptor activation is a reasonable strategy to pursue for the treatment of opioid withdrawal; however, dronabinol is not a likely candidate given its modest withdrawal suppression effects of limited duration and previously reported tachycardia during opioid withdrawal.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Michelle R. Lofwall, Shanna Babalonis, Paul A. Nuzzo, Samy Claude Elayi, Sharon L. Walsh,